BRAF and non-small cell lung carcinoma: Even if the mutation rates of driver genes, including BRAF and MET are low [10, 11], the development and application of targeted therapy drugs is still quite important, which can be used to improve the survival outcomes of NSCLC patients due to the base number of NSCLC patients is large.